Thu, September 29, 2011
[ Thu, Sep 29th 2011 ]: Market Wire
Illumina Introduces Low-Cost Bovine BeadChip for Genotyping of Dairy Cattle
[ Thu, Sep 29th 2011 ]: Market Wire
Chronic Conditions Cost UK Economy More Than 20 Billion Pounds a Year
Wed, September 28, 2011
[ Wed, Sep 28th 2011 ]: Market Wire
Five Days Remain before Deadline in Class-action Lawsuit against Dendreon, Says Hagens Berman
[ Wed, Sep 28th 2011 ]: Market Wire
HeartWare Announces Presentation of Clinical Data .. tion for Cardio-Thoracic Surgery (EACTS) Annual M
[ Wed, Sep 28th 2011 ]: Market Wire
BioDelivery Sciences Announces Results from Phase .. cacy Study for BEMA Buprenorphine in Chronic Pain
[ Wed, Sep 28th 2011 ]: Market Wire
Experts to Provide Successful Strategies for Glob .. ent and Commercialization at PAREXEL Tokyo Semina
[ Wed, Sep 28th 2011 ]: Market Wire
Boston Scientific Announces Favorable Appellate C .. ming Non-Infringement of Johnson & Johnson Patent
[ Wed, Sep 28th 2011 ]: Market Wire
Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals
[ Wed, Sep 28th 2011 ]: Market Wire
IntegraMed Promotes Tim Sheehan to SVP and CFO
[ Wed, Sep 28th 2011 ]: Market Wire
ImmunoCellular Therapeuticsa? ICT-107 Recognized .. hovera?s Top 10 Most Licensable Oncology Products
[ Wed, Sep 28th 2011 ]: Market Wire
Amyris e Michelin Anunciam Colaborao para Desenvolver e Comercializar Isopreno de Fontes Renovveis
Tue, September 27, 2011
[ Tue, Sep 27th 2011 ]: Market Wire
Medtronic Announces Start of Pivotal Trial for En .. TM Transcatheter Aortic Valve Implantation System
[ Tue, Sep 27th 2011 ]: Market Wire
Catasys Launches Its Integrated Substance Dependence Program in Massachusetts
[ Tue, Sep 27th 2011 ]: Market Wire
Merck Names Cuong Viet Do as Chief Strategy Officer
[ Tue, Sep 27th 2011 ]: Market Wire
POZEN Announces October 4, 2011 Mid-Quarter Update and Financial Guidance Webcast
[ Tue, Sep 27th 2011 ]: Market Wire
Transcend/Salar Announce Single Source Solution f .. dvanced, Physician-Centric Clinical Documentation
[ Tue, Sep 27th 2011 ]: Market Wire
BioLineRx to Present Data from the Successfully C .. L-1020 at European Conference on Schizophrenia Re
[ Tue, Sep 27th 2011 ]: Market Wire
Gallup, Healthways Release Inaugural Well-Being Index Results for Germany
[ Tue, Sep 27th 2011 ]: Market Wire
Molina Healthcare Names Michael Steele as Senior Vice President of Dual Eligible Strategies
[ Tue, Sep 27th 2011 ]: Market Wire
Alexion recibe opinin positiva del CHMP para Soli .. s con sndrome ur©mico hemoltico atpico (aHUS) en
[ Tue, Sep 27th 2011 ]: Market Wire
Evidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCO
Mon, September 26, 2011
[ Mon, Sep 26th 2011 ]: Market Wire
InSite Vision Selects Quintiles as Contract Resea .. le Phase 3 Clinical Trial of AzaSite Plusa" and D
[ Mon, Sep 26th 2011 ]: Market Wire
NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer
[ Mon, Sep 26th 2011 ]: Market Wire
Zynex Receives FDA 510(k) Clearance for the NexWave Medical Device
[ Mon, Sep 26th 2011 ]: Market Wire
Alnylam Initiates Phase I Clinical Study of ALN-P .. ting PCSK9 for the Treatment of Severe Hyperchole
[ Mon, Sep 26th 2011 ]: Market Wire
Synta Announces Presentation of Results of Ganete .. udy in Combination with Docetaxel in Solid Tumors
[ Mon, Sep 26th 2011 ]: Market Wire
iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
[ Mon, Sep 26th 2011 ]: Market Wire
ARIAD Announces Long-Term Follow Up of Patients w .. stant CML Treated with Ponatinib in Phase 1 Trial
[ Mon, Sep 26th 2011 ]: Market Wire
Millennium y Seattle Genetics presentan datos cln .. uximab Vedotin) en pacientes peditricos en reunin
[ Mon, Sep 26th 2011 ]: Market Wire
National Hospice and Palliative Care Expert Joins Amedisys
Sat, September 24, 2011
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent, la?oc .. de la?EMCC, des donn©es cliniques concernant la?
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium und Seattle Genetics legen auf der EMC .. n zu ADCETRISa" (Brentuximab Vedotin) bei pdiatri
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent la?occ .. e la?EMCC des donn©es cliniques concernant la?ut
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent, .. r©union annuelle de la?EMCC,;;; des
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent, .. la r©union annuelle de la?EMCC,;;;&#
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent, .. de la r©union annuelle de la?EMCC,;;&#
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent, .. occasion de la r©union annuelle de la?EMCC,&#
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium et Seattle Genetics pr©sentent, .. la?occasion de la r©union annuelle de la?EMCC&#
[ Sat, Sep 24th 2011 ]: Market Wire
Millennium and Seattle Genetics Present Clinical .. mab Vedotin) in Pediatric Patients at EMCC Annual
Fri, September 23, 2011
[ Fri, Sep 23rd 2011 ]: Market Wire
Soliris® (eculizumab) approvato dalla FDA per tu .. fetti da sindrome emolitico uremica (SEU) atipica
[ Fri, Sep 23rd 2011 ]: Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Allos Therapeutics, Inc.
[ Fri, Sep 23rd 2011 ]: Market Wire
Alexion ontvangt positieve CHMP-aanbeveling voor .. nten met atypisch hemolytisch uremisch syndroom i
[ Fri, Sep 23rd 2011 ]: Market Wire
Soliris (eculizumab) goedgekeurd door FDA voor al .. met atypisch hemolytisch uremisch syndroom (aHUS)
[ Fri, Sep 23rd 2011 ]: Market Wire
Celgene: reglementaire update inzake REVLIMID
[ Fri, Sep 23rd 2011 ]: Market Wire
Europischer CHMP erkennt positives Gutachten zu E .. verabreichten aus einer einzigen Tablette besteh
[ Fri, Sep 23rd 2011 ]: Market Wire
Glancy Binkow & Goldberg LLP Announces Investigation of American Medical Alert Corp.
[ Fri, Sep 23rd 2011 ]: Market Wire
Tunstall Healthcare Group Limited neemt AMAC over
[ Fri, Sep 23rd 2011 ]: Market Wire
Two Veteran HCA Leaders Get New Responsibilities

Millennium y Seattle Genetics presentan datos clnicos sobre ADCETRISTM (Brentuximab Vedotin) en pacientes peditricos en reunin

CAMBRIDGE, Mass. & BOTHELL, Wash.--([ BUSINESS WIRE ])--[ Millennium: The Takeda Oncology Company ], una filial propiedad al 100% de Takeda Pharmaceutical Company Limited (TSE:4502) y Seattle Genetics, Inc. (Nasdaq: SGEN), ha presentado los datos de un anlisis retrospectivo de los pacientes peditricos (de 12 a 17 aos) inscritos en cuatro ensayos clnicos multicentro (dos de fase I y dos de fase II) de ADCETRIS. Todos los pacientes fueron diagnosticados con linfoma de Hodgkin recurrente o refractario (HL) (n=5) o linfoma anaplstico sist©mico de c©lulas grandes (sALCL) (n=4) y no han tenido ©xito con al menos un r©gimen de quimioterapia anterior. Los datos se han presentado en una sesin en el Congreso Europeo Multidisciplinario sobre el Cncer, que se celebra del 23 al 27 de septiembre en Estocolmo (Suecia).